Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials

Abstract

ObjectivesTo assess the efficacy and safety of omalizumab for chronic rhinosinusitis with nasal polyps (CRSwNP) and to identify evidence gaps that will guide future research on omalizumab for CRSwNP.DesignSystematic review and meta-analysis.Data sourcesA comprehensive search was performed in PubMed, Embase, Web of Science and the Cochrane Library on 13 October 2020.Eligibility criteriaRandomised controlled trials (RCTs) comparing omalizumab with placebo, given for at least 16 weeks in adult patients with CRSwNP.Data extraction and synthesisTwo independent authors screened search results, extracted data and assessed studies using the Cochrane risk of bias tool. Data were pooled using the inverse-variance method and expressed as mean differences (MDs) with 95% CIs. Heterogeneity was assessed by the χ2 test and the I2 statistic.ResultsA total of four RCTs involving 303 participants were identified. When comparing omalizumab to placebo, there was a significant difference in Nasal Polyps Score (MD=−1.20; 95% CI −1.48 to −0.92), Nasal Congestion Score (MD=−0.67; 95% CI −0.86 to −0.48), Sino-Nasal Outcome Test-22 (MD=−15.62; 95% CI −19.79 to −11.45), Total Nasal Symptom Score (MD=−1.84; 95% CI −2.43 to −1.25) and reduced need for surgery (risk ratio (RR)=5.61; 95% CI 1.99 to 15.81). Furthermore, there was no difference in the risk of serious adverse events ((RR=1.40; 95% CI 0.29 to 6.80), adverse events (RR=0.83; 95% CI 0.60 to 1.15) and rescue systemic corticosteroid (RR=0.52; 95% CI 0.17 to 1.61).ConclusionsThis was the first meta-analysis that identified omalizumab significantly improved endoscopic, clinical and patient-reported outcomes in adults with moderate to severe CRSwNP and it was safe and well tolerated.PROSPERO registration numberCRD42020207639.

Efficacy and Safety of Anti-Interleukin-5 Therapies in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

“…We performed a systematic review and meta-analysis based on a priori protocol that was registered with PROSPERO (no. CRD42021276867) [15]. This review was reported according to the PRISMA extension statement [16].…”

“…Dupilumab improves the disease-specific HRQL and reduces disease severity [8]. Omalizumab significantly improves endoscopic, clinical, and patient-reported outcomes in moderate to severe CRSwNP and is safe and well tolerated [9].…”

Advances in chronic rhinosinusitis in 2020 and 2021

“…The first meta-analysis on the efficacy of omalizumab in CRSwNP confirmed the improvement in NPS and symptoms, and reduced the need for surgery of omalizumab-treated patients compared with placebo. 145 An indirect comparison between dupilumab SINUS 24 and 52 and omalizumab POLYP 1 and 2 showed significantly greater improvements in favor of dupilumab for NPS of 1 point or greater and 2 points or greater, and nasal congestion score of 1 point or greater, but not for the SNOT-22 at week 24. 146 Oykhman et al 147 compared the efficacy of mAbs and aspirin desensitization in patients with CRSwNP, demonstrating that dupilumab and omalizumab improved SNOT-22 likely superior to aspirin desensitization.…”

Biological Therapy of Severe Asthma and Nasal Polyps

“…A systematic review and meta-analysis of four randomized controlled trials including 303 patients aimed to assess the efficacy and safety of omalizumab for CRSwNP. Omalizumab significantly improved nasal polyps score, nasal congestion, SNOT-22 and total nasal symptom score and reduced the need for surgery in adults with moderate-to-severe CRSwNP, and it was safe and well tolerated [ 74 ].…”